natgillin/translations-raw huggingface dataset:
contacting a test compound with a host cell or with membrane of a host cell comprising a G protein-coupled receptor, wherein the G protein-coupled receptor comprises an amino acid sequence selected from the group consisting of: amino acids 1-335 of SEQ ID NO:2; amino acids 2-335 of SEQ ID NO:2; 
(x) stavljanje u doticaj test spoja sa stanicom domačina ili s membranom stanice domaćina, koji sadrži receptor vezanih G-proteina, pri čemu receptor vezanih G-proteina sadrži sekvencu amino kiseline odabranu iz skupine koja sadrži: (i) amino kiseline 1-335 od SEQ ID NO:2; (ii) amino kiseline 2-335 od SEQ ID NO:2;
As an alternative or in addition to filling from bottom to top (or lengthwise), the transverse channel or another formation extending from left to right (in FIG. 3) may be used for the filling medium. 
Kao alternativno ili dodatno uz punilo od dna do vrha (ili uzdužno), za punilo se može upotrijebiti poprečni kanal i neki drugi oblik koji se proteže s lijeva na desno (slika 3).
The pharmaceutical composition for use of any one of claims 7-9, wherein said treatment is by a route of administration selected from the group consisting of oral administration, intravenous administration, subcutaneous administration, topical administration, and inhalation; and preferably by oral administration; or by injection. 
Farmaceutski pripravak za uporabu prema bilo kojem od patentnih zahtjeva 7-9, naznačen time što je navedeno liječenje putem primjene koji je odabran iz skupine koju čine oralna primjena, intravenska primjena, supkutana primjena, topikalna primjena i inhalacija; te poželjno oralnom primjenom; ili injekcijom.
A human engineered DKK-1 antibody for use according to any one of claims 1 to 3, wherein the human engineered DKK-1 antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 18 and a light chain comprising the amino acid sequence of SEQ ID NO: 20. 
Ljudsko konstruirano protutijelo protiv DKK-1, namijenjeno upotrebi u skladu s bilo kojim od patentnih zahtjeva 1 do 3, naznačen time što ljudsko konstruirano protutijelo protiv DKK-I sadrži teški lanac koji ima aminokiselinski slijed sa SEQ ID NO: 18 1 laki lanac koji ima aminokiselinski slijed sa SEQ ID NO: 20.
Added to this was 2,4-difluorobenzonitrile (7.6 g, 55 mmol) and the mixture was stirred at 85° C. for 3 h. 
Ovome je dodan 2,4-difluorobenzonitril (7.6 g, 55 mmol) i smjesa je miješana na 85*C 3 sata.
The watermark generator according to one of claims 1 to 8, wherein the watermark generator is configured to spread information units of the combined information-synchronization representation in a second spreading direction. 
Generator vodenog žiga prema jednom od zahtjeva 1 do 7, naznačen time, da je uređaj za umetanje sinhronizacije konfiguriran za višestruko kombiniranje prikaza proširene informacije s nizom proširene sinhronizacije na elementaran način, u svrhu sastavljanja prikaza informacije i sinhronizacije.
The present invention relates to a concentrated polymeric composition which comprises: a) vinyl aromatic polymers and/or copolymers in an amount ranging from 10% to 90% by weight, calculated with respect to the overall composition, with respect to the overall composition, b) at least one compound containing epoxy functional groups in an amount ranging from 0.01% to 5% by weight, calculated with respect to the overall composition, with respect to the overall composition, c) at least one infrared absorbing agent, in an amount ranging from 10% to 90% by weight, calculated with respect to the overall composition, with respect to the overall composition. 
HR P20171395 T1 PATENTNI ZAHTJEVI Koncentrirana polimerna mješavina, naznačena time što sadrži: a) - vinilaromatske polimere i/ili vinilaromatske kopolimere u količini koja iznosi najmanje 10%, težinski, zračunato s obzirom na ukupnu mješavinu, b) najmanje jedan spoj koji sadrži epoksi funkcionalne skupine u količini koja se kreće u rasponu od 0,01% do 5%, težinski, zračunato s obzirom na ukupnu mješavinu, €) najmanje jedno sredstvo za apsorbiranje infracrvenog zračenja, u količini koja iznosi najmanje 10%, težinski, zračunato s obzirom na ukupnu mješavinu.
Use of adherent cells from a tissue selected from the group consisting of a placenta and an adipose tissue for the manufacture of a medicament identified for treating a medical condition requiring connective tissue regeneration and/or repair. 
Adherentne stanice iz posteljice ili masnog tkiva, naznačene time što su namijenjene upotrebi u liječenju stanja koje se bira iz skupine koju čine ishemija, stanje kod kojeg je potrebno regeneriranje vezivnog tkiva i stanje kod kojeg je potreban popravak vezivnog tkiva.
The present invention relates to a belling machine for forming sockets on the ends of pipes made of thermoplastic material. 
Stroj za oblikovanje u zvono za oblikovanje čahura na krajevima cijevi izrađenih od termoplastičnog materijala, koji se sastoji od:
for one to two weeks and afterwards up-titrated to 200 mg b.i.d.. 
u trajanju od jednog do dva tjedna te nakon toga titriranjem do 200 mg b.i.d.
a frame on which are mounted the pair of cutting devices and the support surface, wherein the frame is configured to be placed on a ground surface; 
okvir (1) na koji su montirani par reznih uređaja i poželjno nosiva površina, pri čemu je okvir konfiguriran tako da se postavlja na površinu tla;
A mildly exothermic reaction ensued and the initially clear solution set up as a solid mass. 
Nastaje blago egzotermna reakcija i na početku bistra otopina zategne se kao kruta masa.
Y represents C1-4alkyl, C2-4alkenyl or C2-4alkynyl, all of which optionally substituted with up to three halogens; 
Y predstavlja C1-4alkil, C2-4alkenil ili C2-4alkinil, od kojih su svi po izboru supstituirani sa do tri halogena;
selecting, by the processor, one or more of the events based on a profile index associated with the respective event and on at least one attribute derived from the respective event, the profile index relating to the link on which the vehicle was travelling at a point during the respective event, wherein the profile index relating to the link is derived at least from the one or more of the link indexes relating to one or more features of the link that influence a behaviour of the driver of the vehicle travelling along the link; 
Računalno implementirani postupak za profiliranje vozača koji se sastoji od Identificiranje (3) događaja u podacima koji se odnose na kretanje vozila, događaji koji uključuju ubrzanje i/ili kočenje naznačen time da se identificira brzina kojom se vozilo kretalo kada je nastupio navedeni događaj; Odabira jednog ili više događaja temeljenih na indeksiranim profilima povezanim sa navedenim događajima 1 na najmanje jednom atributu deriviranom iz navedenog događaja, indexirani profil povezan barem prema poveznici kojom je se vozilo kretalo u trenutku navedenog događaja; utvrđivanje (4) profila vozača (24) iz odabranog događaja; i određivanje (9) ponašanja u vožnji vozača temeljem vozačevog profila.
The high protein, fruit-flavoured beverage according to claim 1 or 2, wherein the total protein: ash content weight ratio of the denatured whey protein composition is at least 15, preferably at least 20, and even more preferably at least 30, such at least 40 or at least 50. 
Visokoprotetnski napitak s voćnom aromom u skladu s patentnim zahtjevom 1 ili 2, naznačen time što je težinski omjer ukupni protein:sadržaj pepela u pripravku denaturiranog proteina sirutke najmanje 15, po mogućnosti najmanje 20, a još poželjnije najmanje 30, primjerice najmanje 40 ili najmanje 50.
A method for decreasing the number of inflammatory lesions (AN count) in a subject having moderate to severe hidradenitis suppurativa (HS), said method comprising systemically 
Anti-TNFa protutijelo za uporabu prema zahtjevu 1, naznačeno time, da anti-TNFa protutijelo smanjuje broj inflamatornih lezija (broj AN) kod subjekta, nadalje gdje se anti-TNFa protutijelo primjenjuje sistemski kod subjekta.
The compound of claim 6 where X is phenyl, optionally substituted with 1 or 2 fluoro, chloro, methyl, hydroxy, methoxy, or trifluoromethyl groups. 
Spoj iz zahtjeva 4, naznačen time, da Y je fenil, po izboru supstituiran sa 1 ili 2 fluoro, kloro, metil, hidroksi, metoksi ili triflormetilnom skupinom.
The method according to claim 14 wherein the physiological signal is an ECG signal. 
Postupak u skladu s patentnim zahtjevom 14, naznačen time da je fiziološki signal EKG signal.
A compound represented by formula (IV), (V), (VI) or (VII); or a pharmaceutically acceptable salt thereof, wherein ---------- represents a single or double bond; 
HR P20150947 T1 PATENTNI ZAHTJEVI Spoj prikazan s formulom (TV), (V), CVD) ili (VID);
The method as in item 1, wherein the panel is a floor panel. 
Postupak prema zahtjevu 1, naznačen time da ploča je podna ploča.
The term “therapeutically effective amount” means the amount of compound/composition that will elicit the desired biologic or medicinal response of a tissue, system or mammal that is being sought by the researcher, physician or clinician. 
Termin "terapijski djelotvorna količina" znači količina spoja odnosno pripravka koja postiže željeni biološki ili medicinski odgovor tkiva, sustava ili sisavca kojeg želi postići istraživač, liječnik ili kliničar.
The polypeptide complex of claim 22, in which the heavy chain Fv fragment of a monovalent Fab forming the T cell receptor-binding domain is linked to one of the polypeptides forming the Fc domain via a CH1 domain and the light chain Fv fragment of the Fab is linked to a CL domain; and the light chain Fv fragment of Fab forming the antigen-binding domain is linked to the other polypeptide forming the Fc domain via a CH1 domain and the heavy chain Fv fragment of the Fab is linked to a CL domain. 
Fv fragment teškog lanca jednovalentnog Fab koji tvori domenu za vezanje na antigen je vezan na jedan od polipeptida koji tvore Fc domenu preko domene CH1, a Fv fragment lakog lanca Fab je vezan na domenu CL; i Fv fragment lakog lanca Fab koji tvori domenu za vezanje na CD3 je vezan na drugi polipeptid koji tvori Fc domenu preko domene CH1, a Fv fragment teškog lanca Fab je vezan na domenu CL;
Cell pellets were resuspended in harvest buffer (20 mM HEPES, 10 mM EDTA, pH 7.4) and homogenized with 4×10 second bursts of a 12 mm Polytron homogenizer, setting 5. 
Pelete stanica su resuspendirane u puferu za skupljanje (20 mM EPES, 10 mM EDTA, pH 7,4) i homogenizirane sa 4 X 10 drugog sredstva za razgradnju od 12 mm Polytron homogenizatora, položaj 5.
Brief Description of the Several Views of the Drawings 
Broj objave europskog patenta:
contacting a G protein-coupled receptor with an optionally labeled known ligand to the receptor in the presence or absence of a test compound, wherein the G protein-coupled receptor comprises an amino acid sequence selected from the group consisting of: 
(a) stavljanje u doticaj receptora vezanih G-proteina sa opcijski obilježenim poznatim ligandom za receptor, u prisutnosti ili u odsutnosti test spoja, pri čemu receptor vezanih G-proteina sadrži sekvencu amino kiseline odabranu iz skupine koja sadrži:
when subject to autoactivating conditions, a mature type I elastase is produced. 
(b) kada podliježe autoaktivacijskim uvjetima, proizveden je zreli tip I elastaze.
(In the above scheme the definition of R1, R3,R4, m, o, p and q are the same as already described.) 
(U Shemi, gore, definicija R1, R3,R4, m, 0, p iq je ista kao što je jeveć opisano.)
The process according to claim 1, which further comprises denoxing the flue gases to at least 60%. 
Postupak prema jednom zahtjevu od 1 do 4, naznačen time da su dimni plinovi (A) denitrificirani do barem 60%.
A video decoding method using intra prediction, the video decoding method comprising: obtaining, from a bitstream, a most probable mode flag indicating whether one of candidate intra prediction modes is used to determine an intra prediction mode of a current block; 
- < dobivanje iz toka bitova, zastavice najvjerojatnijeg načina, koja označava da li je upotrijebljen jedan od kandidata načina unutrašnjeg predviđanja, za određivanje načina unutrašnjeg predviđanja trenutnoga bloka;
at least one fuel activation and energy release apparatus, comprising: 
najmanje jedan uređaj (100) za aktivaciju goriva i otpuštanje energije koji sadrži:
means for holding a dispensing tube 10 under sterile conditions during transport in the form of a space, where the dispensing tube can be rolled up (not shown); 
- > sredstvo za držanje cijevi za točenje 10 pod sterilnim uvjetima tijekom transporta u obliku prostora u kojem se cijev za točenje može smotati (nije prikazano);
A compound for use as defined in claim 13 wherein the cognitive disorder is a cognitive disorder associated with a disease selected from the group consisting of schizophrenia, bipolar affective disorder, Alzheimer's disease and Parkinson's disease. 
Spoj namijenjen upotrebi u skladu s patentnim zahtjevom 12, naznačen time što je kognitivni poremećaj kognitivni poremećaj povezan s bolešću koju se bira iz skupine koju čine shizofrenija, bipolarni afektivni poremećaj, Alzheimerova bolest i Parkinsonova bolest.
Figure 2a shows the situation where the container 2 has been placed on the base part 5 and the cover 6 is mounted and secured to the base part by means of the locking ring 14 as described above. 
HR P20070257 T3 Slika 2a prikazuje situaciju kad je spremnik 2 postavljen na osnovni dio 5 i pokrov 6 je montiran i učvršćen na osnovni dio pomoću prstena 14 za zabravljivanje, kao što je gore opisano.
The conjugate of claim 4, wherein the payload comprises a cytotoxic compound. 
Konjugat iz patentnog zahtjeva 4, gdje dio od značaja sadrži citotoksični spoj.
A method according to any of the preceding claims, whereby the waste mineral wool is milled and has a water content of 10-15 % by weight prior to being supplied. 
Postupak sukladno bilo kojem od prethodnih zahtjeva, pri čemu je otpadna mineralna vuna s udjelom vode od 10-15 % po težini prije opskrbe
5 of the 2005/0020612 patent application): 
Datum objave europske prijave patenta:
Y represents a group of formula 
Y predstavlja skupinu formule
as a biocidal composition in an aqueous preparation comprising strains of bacteria selected from the group consisting of Methylobacteria and Pseudomonas which are resistant to, tolerant to and/or degrade aldehyde-releasing biocides and/or biocides with one or more aldehyde groups in absence of lithium ions. 
Postupak u skladu s patentnim zahtjevima 1 ili 2, pri čemu je navedeni topljivi litijev sastojak dodan prije navedenog biocida koji otpušta aldehid i/ili biocida s jednom ili više aldehidnih skupina.
Chem. 40, 1997, 2674-2687) with a 5-halo- or 5-pseudohalo indole by methods analogous to those described in the literature e.g. Schopfer, U.; Schlapbach, A. Tetrahedron; 57, 2001, 3069-3073, where “halo” is either bromo or iodo or “pseudohalo” is e.g. triflate or nonaflate. 
Chem. 40, 1997, 2674-2687) 5halo ili 5-pseudohalo indol metodama analognim onima opisanim u literaturi, npr. Schopfer, U.; Schlapbach, A.;
System according to one of claims from 1 to 4, wherein said operating unit (11) is so configured as to alert said central unit (15) after a given period of correct connection of said piece of equipment (1) to the main supply of electricity, independently of any other alert. 
Sustav prema jednom od zahtjeva od 1 do 3, naznačen time da je navedena radna jedinica (11) konfigurirana tako da upozori navedenu centralnu jedinicu (15) nakon zadanog perioda pravilne priključenosti navedenog komada opreme (1) na glavnu opskrbu električnom energijom, neovisno o bilo kojem drugom upozorenju.
This invention relates to a process for producing a multiplicity of microfluidic arrangements, particularly nozzle arrangements, from a plate-shaped composite structure comprising groove structures with dimensions in the micrometre range, in particular to a process according to the preamble of claim 1. 
Ovaj izum se odnosi na postupak za proizvodnju više mikrofluidnih naprava, posebno naprava s mlaznicom, od pločaste kompozitne strukture koja ima brazdastu strukturu s dimenzijama u mikrometarskom području, posebno na postupak prema uvodnom dijelu prvog patentnog zahtjeva.
In accordance with the invention, the new and improved process resides in the application to the exterior surface of post-harvest produce of an improved coating composition comprising an aqueous emulsion from about 0.25 to about 25 percent by weight polyvinylidene chloride copolymer, and from about 0.0001 to 10 percent surfactant, preferably Triton-X. 
U skladu sa izumom, novi i poboljšani postupak predstavlja primjenu na vanjsku površinu ubranog proizvoda poboljšane smjese za oblaganje koja sadrži vodenu emulziju od 0.25 do 25 mas% poliviniliden klorid kopolimera, i od 0.0001 do 10 % površinski aktivnog sredstva, poželjno Triton-X.
Said heterocyclic five- or six-membered aromatic ring condensed with the said five- or six-membered aromatic ring may contain 1, 2 or 3 nitrogen atoms where it is a six-membered ring, or 1, 2 or 3 heteroatoms selected from oxygen, nitrogen and sulfur where it is a five-membered ring. 
Spomenuti heterociklički petero- ili šesteročlani aromatski prsten spojen sa spomenutim petero- ili šesteročlanim aromatskim prstenom može sadržavati 1, 2 ili 3 dušikova atoma gdje je on šesteročlani prsten, ili 1, 2 ili 3 heteroatoma odabranih između kisika, dušika i sumpora, gdje je on peteročlani prsten.
The topical veterinary composition of paragraph 13, wherein the insect growth regulator is (S)-methoprene, pyriproxyfen, hydroprene, cyromazine, fluazuron, lufenuron, or novaluron. 
Topikalni veterinarski pripravak prema zahtjevu 10, naznačen time, da je regulator rasta kukaca (S)-metopren, piriproksifen, hidropren, ciromazin, fluazuron, lufenuron ili novaluron.
A method of treating ulcerative colitis, the method comprising administering to a subject in need thereof a therapeutically effective amount of an IL-22 Fc fusion protein consisting of the amino acid sequence of SEQ ID NO:8. 
Farmaceutski pripravak za uporabu prema bilo kojem od zahtjeva 28 do 34, naznačen time, da farmaceutski pripravak obuhvaća fuzijski protein Fc IL-22 koji obuhvaća ili se sastoji od aminokiselinske sekvence od SEQ ID NO:8 ili SEQ ID NO:10.
optionally adding a sugar, an amino acid and/or a detergent to the solution, 
dodavanje šećera i deterdženta u otopinu,
The method of claim 1, wherein the antibody exhibits one or a combination of the following properties: 
Antitijelo, ili njegov antigen-vezujući dio, bilo kojeg od prethodnih patentnih zahtjeva, koji pokazuje jednu ili kombinaciju sljedećih svojstava:
wherein R4 is a member selected from alkyl, substituted alkyl, aryl, substituted aryl, heteroaryl and substituted heteroaryl; 
[image] gdje je R4 član odabran alkila, supstituiranog alkila, arila, supstituiranog arila, heteroarila i supstituiranog heteroarila;
The process of claim 17, wherein in step b), the mixture obtained in step a) is reacted with an acid until at least 98% of the tertiary amino groups have been protonated and said acid is a carboxylic acid having 1 to 3 carbon atoms. 
Postupak prema zahtjevu 10 ili 11, naznačen time da kiselina je karboksilna kiselina koja ima 1 do 3 ugljikovih atoma.
The container assembly according to claim 1, wherein at least two sides of the polygonal cross-section comprise self-complementary interlocking features. 
Sklop spremnika (1) prema zahtjevu 1 ili 2, naznačen time što najmanje dvije, te poželjno četiri strane poligonalnog poprečnog presjeka obuhvaćaju samo-komplementarne međusobno povezujuće značajke (30, 31).
A seed comprising the composition of claim 1. A method for modulating (i) growth of a plant, or (ii) germination of a seed of said plant, the method comprising contacting said plant or its seed or its growth substrate with the composition of claim 1 or 2 in an amount of said composition effective to modulate said growth of said plant and/or germination of said seed. 
Postupak za modulaciju (i) rasta biljke ili (ii) klijanja sjemena navedene biljke, postupak koji uključuje kontakt navedene biljke ili njenog sjemena ili njenog supstrata za rast sa spojem sukladno zahtjevu 1 ili 2 u količini navedenog spoja, učinkovitog za modulaciju rasta navedene biljke i / ili klijanja navedenog sjemena.
A method of preparing a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof, comprising the steps of: A) reacting compound A: with compound B: to form a compound represented by Structural Formula (XX): and 
7. Postupak za pripremu spoja formule ili njegove farmaceutski prihvatljive soli, koji sadrži korake: i) reagiranja spoja 6: sa spojem 7a: da se formira spoj &a:
The solid form of any one of claims 1 to 4, having a thermal gravimetric analysis plot comprising a mass loss of less than about 0.5% when heated from about 25 °C to about 150 °C. 
Čvrsti oblik u skladu s bilo kojim od patentnih zahtjeva 1 do 4, naznačen time što ima grafički prikaz toplinske gravimetrijske analize koji sadrži gubitak mase manji od otprilike 0,5% prilikom grijanja od otprilike 25%C€ do otprilike 150*C.
A pharmaceutical composition, comprising 3a-hydroxy-3B-methoxymethyl-21-(1'-imidazolyl)-5a-pregnan-20-one or a pharmaceutically-acceptable salt or solvate thereof, and one or more pharmaceutically-acceptable excipients for use in the treatment of obsessive compulsive disorder, post-traumatic stress disorder or social anxiety disorder in a human subject, wherein the composition provides steady state plasma levels of 3a-hydroxy-3B-methoxymethyl-21-(1'-imidazolyl)-5a-pregnan-20-one in a range of from 5 ng/mL to 500 ng/mL for a duration of from 6 hours to 24 hours following administration. 
Farmaceutski sastav za uporabu u liječenju depresije, bolesne potrebe za alkoholom i/ili ovisnosti o alkoholu, predmenstrualne napetosti, predmenstrualnog sindroma ili predmenstrualnog disforičnog poremećaja, naznačen time, da sadrži 3a-hidroksi-3B-metoksimetil-21-(1'-imidazolil)-5a-pregnan-20-on ili njegovu farmaceutski prihvatljivu sol ili solvat i jedan ili više farmaceutski prihvatljivih ekscipijenata, kod čega sastav daje stacionarno stanje razine u plazmi 3a-hidroksi-3B-metoksimetil-21-(1'-imidazolil)-5a-pregnan-20-ona u području od 5ng/ml do 500 ng/ml u trajanju od 12 h do 24 h nakon davanja.
A composition for use in treating moderate to severe hypertriglyceridemia in a subject having a fasting baseline triglyceride level of about 500 mg/dl to about 1500 mg/dl, wherein the composition comprises eicosapentaenoic acid ethyl ester, wherein the eicosapentaenoic acid ethyl ester comprises at least 96%, by weight, of all fatty acids present in the composition, the composition contains not more than 4% by weight, of total fatty acids other than eicosapentaenoic acid ethyl ester, and the composition contains about 0.1% to about 0.6% of at least one fatty acid other than eicosapentaenoic acid ethyl ester and docosahexaenoic acid, and wherein 4 capsules, each containing 1g of the composition, are administered to the subject daily. 
Pripravak namijenjen upotrebi u skladu s patentnim zahtjevom 1, naznačen time što etilni ester ikozapentaenske kiseline sadrži najmanje 96%, težinski, od svih masnih kiselina prisutnih u pripravku, gdje pripravak sadrži najviše 4% težinski, od ukupnih masnih kiselina koje nisu etilni ester ikozapentaenske kiseline, te gdje pripravak sadrži otprilike 0,1% do otprilike 0,6% najmanje jedne masne kiseline koja nije etilni ester ikozapentaenske kiseline i dokozaheksaenska kiselina.